BridgeMD
Individualized Systems Medicine strategy to target cancer stem cells in patients with recurrent Glioblastoma (ISM-GBM)
EU CTIS ID: 2023-510214-11-00
What this study is testing
Establishment and feasability evaluation of high-throuhput drug screens of personalized tumor stem cell cultures. Success of generating an individualized treatment selection based on drug screening.
- Human Pharmacology (Phase I)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Histologically verified glioblastoma
- Must be ambulatory with an ECOG performance status 0-1
- Must be 18 to 70 years of age.
- Adequate bone marrow, liver and heart function
- Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.
You likely can't join if
- Patients taking part in other clinical trials which could make incusion or follow-up difficult
- Any reason why, in the opinion of the investigator, the patient should not participate.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.